SCHEMBL2931686

SCHEMBL2931686

CC(=O)Oc1cc(C(Sc2c(O)ccc(O)c2F)C(=O)c2ccccc2)ccc1O[Si](C(C)C)(C(C)C)C(C)C

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
ALDH1A1 P00352 9/20 0.33
MAPT P10636 4/20 0.33
KDM4E B2RXH2 4/20 0.33
GAA P10253 2/20 0.33
MAPK1 P28482 1/20 0.32
HSD17B10 Q99714 3/20 0.31
ALOX15 P16050 2/20 0.31
TSHR P16473 2/20 0.31
RAB9A P51151 1/20 0.31
HPGD P15428 2/20 0.31
LMNA P02545 2/20 0.31
RECQL P46063 1/20 0.31
TP53 P04637 1/20 0.30
POLB P06746 1/20 0.30
MPO P05164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2937004 0.90 MRGPRX4 (0.35) CYP2C9CYP2C19MAPT
SCHEMBL2931688 0.80 CYP3A4 (0.34) CYP3A4ALDH1A1MAPTKDM4EMAPK1
SCHEMBL2936902 0.76 ALDH1A1 (0.39) CYP3A4CYP1A2CYP2D6CYP2C19ALDH1A1
SCHEMBL2937006 0.76 PTGES (0.36)
SCHEMBL2935373 0.66 LTB4R (0.35) CYP3A4CYP1A2CYP2D6CYP2C19ALDH1A1
SCHEMBL2101678 0.62 ALDH1A1 (0.41) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL16323456 0.59 PIM1 (0.51) CYP3A4CYP2C19ALDH1A1KDM4EGAA
SCHEMBL13984323 0.59 TSHR (0.49) CYP3A4ALDH1A1KDM4EGAATSHR
SCHEMBL2937612 0.58 GAA (0.46) CYP3A4ALDH1A1MAPTKDM4EGAA
SCHEMBL3936561 0.58 TSHR (0.55) CYP3A4ALDH1A1KDM4EGAAALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501819-B1 ESTROGEN RECEPTOR MODULATORS MERCK SHARP & DOHME (US) 2010-09-15 EP disclosed
US-7138426-B2 Estrogen receptor modulators MERCK & CO., INC. (US) 2006-11-21 US disclosed
EP-1501819-A4 ESTROGEN RECEPTOR MODULATORS MERCK & CO INC (US) 2006-06-21 EP disclosed
US-20050234245-A1 Estrogen receptor modulators MERCK SHARP & DOHME CORP. 2005-10-20 US disclosed
EP-1501819-A1 ESTROGEN RECEPTOR MODULATORS Merck & Co., Inc. (US) 2005-02-02 EP disclosed
WO-2003091239-A1 ESTROGEN RECEPTOR MODULATORS MERCK & CO., INC. (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234245-A1 Estrogen receptor modulators ESRRB, ESR2, GPER1 CYP3A4 2328/4885CYP1A2 1878/4885CYP2D6 2510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.